Societe francaise de lutte contre les cancers et les leucemies de lenfant et de ladolescent SFCE

Paris, France

Societe francaise de lutte contre les cancers et les leucemies de lenfant et de ladolescent SFCE

Paris, France
SEARCH FILTERS
Time filter
Source Type

Dubois C.,Paris West University Nanterre La Défense | Morin F.,Paris West University Nanterre La Défense | Moro-Sibilot D.,Paris West University Nanterre La Défense | Langlais A.,Paris West University Nanterre La Défense | And 17 more authors.
Bulletin du Cancer | Year: 2017

Introduction The French Cancer Plan 2014–2019 stresses the importance of strengthening collaboration between all stakeholders involved in the fight against cancer, including cancer cooperative groups and intergroups. This survey aimed to describe the basics characteristics and clinical research activity among the Cancer Cooperative Groups (Groupes coopérateurs en oncologie). The second objective was to identify facilitators and barriers to their research activity. Methods A questionnaire was sent to all the clinicians involved in 2014 as investigators in a clinical trial sponsored by one of the ten members of the Cancer Cooperative Groups network. The questions were related to their profile, research activity and the infrastructure existing within their healthcare center to support clinical research and related compliance activities. Results In total, 366 investigators responded to our survey. The academic clinical trials sponsored by the Cancer Cooperative Groups represented an important part of the research activity of the investigators in France in 2014. These academic groups contributed to the opening of many research sites throughout all regions in France. Factors associated with a higher participation of investigators (more than 10 patients enrolled in a trial over a year) include the existing support of healthcare professionals (more than 2 clinical research associate (CRA) OR = 11.16 [3.82–32.6] compared to none) and the practice of their research activity in a University Hospital Center (CHU) rather than a Hospital Center (CH) (OR = 2.15 [1.20–3.83]). Conclusion This study highlighted factors that can strengthen investigator clinical research activities and subsequently improve patient access to evidence-based new cancer therapies in France. © 2017 Société Française du Cancer

Loading Societe francaise de lutte contre les cancers et les leucemies de lenfant et de ladolescent SFCE collaborators
Loading Societe francaise de lutte contre les cancers et les leucemies de lenfant et de ladolescent SFCE collaborators